|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...7475767778798081828384...156157» |
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Evaluate Effects of Personalized Patient Counselling for Enbrel (clinicaltrials.gov) - Jan 28, 2015
P4, N=300, Not yet recruiting, Sponsor: Amgen
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Monotherapy: A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=71, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change: A Non-Interventional Study Evaluating Rheumatoid Arthritis Participants Treated With Tocilizumab (RoActemra/Actemra) (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=50 --> 80
- ||| Trial completion: A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients. (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=80, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=50 --> 80 Active, not recruiting --> Completed
- | Trial completion: Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=30, Completed, Sponsor: medac GmbH
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: TENOR: Tocilizumab Effect iN pOlymyalgia Rheumatica (clinicaltrials.gov) - Jan 28, 2015
P2, N=21, Completed, Sponsor: University Hospital, Brest
Not yet recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2013 --> Oct 2014
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 28, 2015
P3, N=12, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: Oct 2013 --> Oct 2014 Active, not recruiting --> Completed
- ||| Rituxan (rituximab) / Roche
Trial completion: An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=90, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=81, Completed, Sponsor: Institut fuer Physiotherapieforschung
- | Enrollment closed: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Jan 26, 2015
P3, N=600, Active, not recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| febuxostat / Generic mfg.
New P4 trial: The Effect of Uric Acid Lowering in Type 1 Diabetes (clinicaltrials.gov) - Jan 26, 2015
P4, N=72, Recruiting, Sponsor: University Health Network, Toronto
- | BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
New P1 trial: Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog (clinicaltrials.gov) - Jan 26, 2015
P1, N=38, Recruiting, Sponsor: Adocia
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Phase classification, Enrollment change, Trial primary completion date: SURPRISE: Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation (clinicaltrials.gov) - Jan 26, 2015
P4, N=233, Completed, Sponsor: SURPRISE Study Group
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | Phase classification: PN/A --> P4 | N=300 --> 233 | Trial primary completion date: Oct 2013 --> Dec 2014
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date, Combination therapy, Monotherapy: OSCAR: A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 22, 2015
P3, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Completed | Phase classification: PN/A --> P4 | N=300 --> 233 | Trial primary completion date: Oct 2013 --> Dec 2014 Trial primary completion date: Jul 2015 --> Nov 2015
- Enrollment change, Trial termination, Trial primary completion date: SPARROW: Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (clinicaltrials.gov) - Jan 22, 2015
P3, N=4, Terminated, Sponsor: Nordic Pharma SAS
Trial primary completion date: Jul 2015 --> Nov 2015 N=216 --> 4 | Suspended --> Terminated | Trial primary completion date: Apr 2014 --> Nov 2012; Change of design consideration
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial, Adherence: Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. (clinicaltrials.gov) - Jan 22, 2015
P4, N=450, Not yet recruiting, Sponsor: Biogen Idec
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: REVEAL: Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (clinicaltrials.gov) - Jan 22, 2015
P4, N=540, Recruiting, Sponsor: Biogen Idec
- | Hulio (adalimumab biosimilar) / Viatris, Fujifilm Kyowa Kirin Biologics
Enrollment open: ARABESC: A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jan 22, 2015
P3, N=600, Recruiting, Sponsor: Fujifilm Kyowa Kirin Biologics Co.
N=216 --> 4 | Suspended --> Terminated | Trial primary completion date: Apr 2014 --> Nov 2012; Change of design consideration Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: SEWORRA: Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis (clinicaltrials.gov) - Jan 22, 2015
P4, N=30, Completed, Sponsor: University Hospital, Rouen
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Betaseron (IFN-?-1b) / Bayer
Enrollment change, Immunomodulating: Depression and Fatigue in MS Patients Treated With Betaferon. (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=567, Completed, Sponsor: Bayer
Recruiting --> Completed N=252 --> 567
- lacosamide / Generic mfg.
New P2 trial: Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: (clinicaltrials.gov) - Jan 22, 2015
P2, N=50, Recruiting, Sponsor: Indiana University School of Medicine
- || tibulizumab (ZB-106) / Zura Bio
Enrollment closed: A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jan 22, 2015
P1, N=51, Active, not recruiting, Sponsor: Eli Lilly and Company
N=252 --> 567 Recruiting --> Active, not recruiting
- | Enrollment closed, Stroma: Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis (clinicaltrials.gov) - Jan 22, 2015
P1/2, N=20, Active, not recruiting, Sponsor: Translational Biosciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- warfarin / Generic mfg.
Biomarker, Trial completion, Trial primary completion date: Pharmacogenetics of Warfarin in Puerto Ricans. (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=350, Completed, Sponsor: University of Puerto Rico
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jul 2014
- SAR113244 / Sanofi
Enrollment open: Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients (clinicaltrials.gov) - Jan 21, 2015
P1, N=24, Recruiting, Sponsor: Sanofi
Recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jul 2014 Not yet recruiting --> Recruiting
- ligelizumab (QGE 031) / Novartis
Trial primary completion date: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - Jan 20, 2015
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Mar 2015
- ||| Benlysta (belimumab) / GSK
Trial initiation date: A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (clinicaltrials.gov) - Jan 20, 2015
P2b, N=100, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Nov 2015 --> Mar 2015 Initiation date: Jan 2014 --> May 2014
- ||| sifalimumab (MDX-1103) / AstraZeneca
Phase classification, Enrollment change: A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Subjects With Systemic Lupus Erythematosus or Myositis (clinicaltrials.gov) - Jan 20, 2015
P2, N=260, Active, not recruiting, Sponsor: MedImmune LLC
Initiation date: Jan 2014 --> May 2014 Phase classification: P1/2 --> P2 | N=118 --> 260
- ||| Venoglobulin-IH (polyethylene glycol treated human immunoglobulin G) / Mitsubishi Tanabe
New P3 trial: Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome (clinicaltrials.gov) - Jan 20, 2015
P3, N=25, Recruiting, Sponsor: Japan Blood Products Organization
- | New P1/2 trial: Mindfulness-based Stress Reduction for Multiple Sclerosis (clinicaltrials.gov) - Jan 20, 2015
P1/2, N=60, Not yet recruiting, Sponsor: National College of Natural Medicine
- Lemtrada (alemtuzumab) / Sanofi
Enrollment closed, Metastases: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 20, 2015
P4, N=8, Active, not recruiting, Sponsor: University of Chicago
Phase classification: P1/2 --> P2 | N=118 --> 260 Enrolling by invitation --> Active, not recruiting
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical: A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE) (clinicaltrials.gov) - Jan 20, 2015
P4, N=68, Completed, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Active, not recruiting N=49 --> 68
- || New P3 trial: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Jan 20, 2015
P3, N=200, Recruiting, Sponsor: University of Michigan
- |||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment open: ESCALATE: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (clinicaltrials.gov) - Jan 20, 2015
P4, N=200, Recruiting, Sponsor: Biogen Idec
N=49 --> 68 Not yet recruiting --> Recruiting
- | Promacta (eltrombopag) / Novartis
Trial completion: Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects (clinicaltrials.gov) - Jan 20, 2015
P1, N=39, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Trial primary completion date: PK and PD Study of Natalizumab in Pediatric Subjects With RRMS (clinicaltrials.gov) - Jan 20, 2015
P1, N=13, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014
- MIS416 / Amplia Therap
Trial primary completion date: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 18, 2015
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014 Trial primary completion date: Dec 2015 --> May 2016
- Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Phase classification, Enrollment change, Trial termination, Trial primary completion date: A Research Trial of Aralast in New Onset Diabetes (RETAIN) (clinicaltrials.gov) - Jan 18, 2015
P1, N=17, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2015 --> May 2016 Phase classification: P2 --> P1 | N=32 --> 17 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2013; Due to lack of mechanistic signal and competing industry studies
- ||| Clinical: G7 Acetabular System vs. Exceed ABT Acetabular System in THA (clinicaltrials.gov) - Jan 17, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Biomet, Inc.
- |||||| tofacitinib / Generic mfg.
Head-to-Head: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 17, 2015
P3, N=200, Recruiting, Sponsor: Pfizer
Phase classification: P2 --> P1 | N=32 --> 17 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2013; Due to lack of mechanistic signal and competing industry studies Not yet recruiting --> Recruiting
- Trial primary completion date: Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=30, Recruiting, Sponsor: Jae Ho Byun
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Jun 2015
- Clinical: MCS-III-MOB: Psychometric Properties Mobility Measures MS (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=300, Recruiting, Sponsor: Hasselt University
- ||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Enrollment closed: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 15, 2015
P3, N=467, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Active, not recruiting
- |||| buprenorphine transdermal / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain (clinicaltrials.gov) - Jan 15, 2015
P4, N=119, Completed, Sponsor: Mundipharma Pte Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed | N=230 --> 119 | Trial primary completion date: Aug 2014 --> Jan 2015
- |||| TNF-α kinoid / Neovacs, Debiopharm
Trial completion: Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 15, 2015
P2, N=143, Completed, Sponsor: Neovacs
Recruiting --> Completed | N=230 --> 119 | Trial primary completion date: Aug 2014 --> Jan 2015 Active, not recruiting --> Completed
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Trial primary completion date: Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies. (clinicaltrials.gov) - Jan 15, 2015
P4, N=10, Recruiting, Sponsor: Arthritis Treatment Center, Maryland
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Jul 2015
- Trial primary completion date: Remission Induction and Sustenance in Graves' Disease 2 (clinicaltrials.gov) - Jan 15, 2015
P4, N=250, Active, not recruiting, Sponsor: Aalborg Universitetshospital
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Jan 2015 --> Oct 2015
- ||| Enrollment open: Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=145, Recruiting, Sponsor: Aarhus University Hospital
Trial primary completion date: Jan 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=10, Completed, Sponsor: Northumbria University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Trial completion: Effect of CSII and CGM on Progression of Late Diabetic Complications (clinicaltrials.gov) - Jan 15, 2015
P4, N=60, Completed, Sponsor: Steen Andersen
Active, not recruiting --> Completed Active, not recruiting --> Completed